Iovance Biotherapeutics Inc
IOVA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.65B
Close$
$-0.19
102.4% downside
Current Fair Value
102.4% downsideOvervalued by 102.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3.65 Billion |
|---|---|
| Enterprise Value | $3.58 Billion |
| Earnings per Share | $-1.09 |
| Beta | 0.76 |
| Outstanding Shares | 455,919,000 |
Return
| Return on Equity | -39.33% |
|---|---|
| Return on Assets | -31.62% |
| Return on Invested Capital | -35.73% |
Valuation & Multiples
| P/E Ratio | -15.17 |
|---|---|
| PEG | 26.33 |
| Price to Sales | - |
| Price to Book Ratio | 8.04 |
| Enterprise Value to Revenue | 11.02 |
| Enterprise Value to EBIT | -12.39 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 5, 2026
EPS Estimate
$-0.08
Consensus analyst estimateRevenue Estimate
$115.98 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 23, 2027
EPS Estimate
$-0.11
Consensus analyst estimateRevenue Estimate
$129.13 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 92.13% |
|---|---|
| Total Calls | 2,000▼ 99.96% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.28%▼ 64.09% |
|---|---|
| Total Invested | $18.28M▼ 98.48% |
| Investors Holding | 35▼ 270.00% |
About Iovance Biotherapeutics Inc
975 employees
CEO: Maria Fardis
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology firm committed to advancing and bringing to market innovative cancer immunotherapies. Its fundamental objective is to leverage and direct a patient's own immune system to id...